NIS66.3m market cap
NIS14.59 last close
Based in Israel, BioLight is an emerging ophthalmic company focused on the development and commercialisation of products and product candidates that address ocular conditions. Lead products IOPtiMate and VS-101 are directed towards the treatment of glaucoma.
Investment summary
BioLight raised NIS11.4m (gross) from the issuance of 908,540 shares in May 2018. We believe these funds should allow BioLight to fund its operations until at least H218, at which point we expect it to receive $12m from the second stage (out of four) of the IOPtima divestiture transaction. BioLight expects that upon completion of all stages (ie by mid-2021), it will receive gross proceeds of $23-27.3m for its entire holding.
Y/E Dec |
Revenue (NISm) |
EBITDA (NISm) |
PBT (NISm) |
EPS (NIS) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 2.1 | (20.2) | (26.3) | (5.37) | N/A | N/A |
| 2017A | 1.2 | (26.8) | (26.6) | (5.29) | N/A | N/A |
| 2018E | 0.9 | (24.0) | (26.3) | (5.21) | N/A | N/A |
| 2019E | 0.9 | (24.4) | (26.3) | (5.56) | N/A | N/A |
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (NISm) | 34.2 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Israel Makov | Chairman |
| Suzana Nahum Zilberberg | CEO |
| Itai Bar-Natan | CFO |
